Abstract
The neutralization of VEGF is the current treatment of choice for age-related macular degeneration. Current approaches include anti-VEGF-antibodies and – Fab Fragments, aptamers, soluble receptors (Traps) and siRNA. The molecular properties of VEGF and its antagonists are reviewed and the pathways of action of these substances are discussed.
Keywords: VEGF, ranibizumab, lucentis, AMD, pegaptanib, VEGF-trap
Mini-Reviews in Medicinal Chemistry
Title: Treating Age-Related Macular Degeneration – Interaction of VEGF-Antagonists with their Target
Volume: 9 Issue: 9
Author(s): A. Klettner and J. Roider
Affiliation:
Keywords: VEGF, ranibizumab, lucentis, AMD, pegaptanib, VEGF-trap
Abstract: The neutralization of VEGF is the current treatment of choice for age-related macular degeneration. Current approaches include anti-VEGF-antibodies and – Fab Fragments, aptamers, soluble receptors (Traps) and siRNA. The molecular properties of VEGF and its antagonists are reviewed and the pathways of action of these substances are discussed.
Export Options
About this article
Cite this article as:
Klettner A. and Roider J., Treating Age-Related Macular Degeneration – Interaction of VEGF-Antagonists with their Target, Mini-Reviews in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/138955709788922665
DOI https://dx.doi.org/10.2174/138955709788922665 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Colon Cancer and Specific Ways to Deliver Drugs to the Large Intestine
Anti-Cancer Agents in Medicinal Chemistry Applications of Venom Proteins as Potential Anticancer Agents
Protein & Peptide Letters Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals
Current Medical Imaging ErbB Antagonists Patenting: “Playing Chess with Cancer”
Recent Patents on Biotechnology Epigenomics
Current Drug Metabolism Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design The Mutator Phenotype in Cancer: Molecular Mechanisms and Targeting Strategies
Current Drug Targets Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All
Current Pharmaceutical Design The Weal and Woe of Costimulation in the Adoptive Therapy of Cancer with Chimeric Antigen Receptor (CAR)-Redirected T Cells
Current Molecular Medicine Meet the Editorial Board:
Current Genomics The Molecular Machinery Regulating Apoptosis Signal Transduction and its Implication in Human Physiology and Pathophysiologies
Current Molecular Medicine Natural Carriers for siRNA Delivery
Current Pharmaceutical Design Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
Current Pharmaceutical Biotechnology Subject Index To Volume 5
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry